Boehringer Ingelheim Venture Fund

Established in 2010, the Boehringer Ingelheim Venture Fund (BIVF) is a €350M evergreen corporate venture fund with a global presence in the EU, US, and China. As a dedicated Seed/Series A investor with company formation expertise, BIVF primarily invests in pre-clinical assets and platforms, targeting first-in-class, disease-modifying therapeutics across various modalities. Its focus areas are cancer (immuno-oncology & targeted therapy), regenerative medicine (including cell reprogramming & neurodegeneration), auto-immunity, digital solutions supporting the pharma value chain, and infectious diseases (with a focus on AMR). BIVF's activities are closely aligned with Boehringer Ingelheim's strategic interests, fostering potential business development targets. The fund targets unprecedented therapeutic concepts addressing high medical needs — including novel platform technologies to address undruggable targets, new-generation vaccines, and new biological entities — and takes a minority shareholder position with a voting board seat to actively support portfolio companies. Its evergreen structure allows it to support companies across the extended development timelines that novel therapeutics require.